CATALYST DOSSIER · UPDATED 2026-11-18
$OPCH
biotech · convergence -9 · conviction WATCH
Price & Live Quote Loading live quote & chart…
Practice trade tools Build a reference frame, save a practice trade, or preview a draft. No brokerage order is placed.
Paper trade unavailable: missing risk-bounded frame
Reference only. Not financial advice. No brokerage order is placed.
Why $OPCH?
Quantitative
Net Income (CY2026Q2) : $53.9M (+6.7% YoY)
Catalysts
Multi-spoke convergence : 6 convergent signals fired: sc13d, m_proxy, auto_sec_despac, auto_macro_adp_payrolls, auto_macro_bls_employment
Risks
Auditor change / restatement : audit_opinion on
Bear case
Multiple compression : If breadth deteriorates, biotech-wide multiples re-rate lower regardless of pick-specific thesis
Sympathy basket (cerebro)
MG via industrials r=+0.85 sympathetic (score 15)
MMM via industrials r=+0.85 sympathetic (score 14)
PVL via materials r=+0.82 sympathetic (score 23)
FRTT via materials r=+0.82 sympathetic (score 5)
NVDA via semis r=+0.69 sympathetic (score 6)
FLEX via semis r=+0.69 sympathetic (score 3)
Signals Firing
sc13d m_proxy auto_sec_despac auto_macro_adp_payrolls auto_macro_bls_employment auto_macro_durable_goods
Pick Track Record Date List Next-day max run Next-day close Hit +2%? 2026-11-04 sec_top_gappers +0.4% -0.5% — 2026-11-04 sec_top_moat_emerging +0.4% -0.5% — 2026-10-08 sec_top_gappers +0.2% +0.1% — 2026-10-08 sec_top_moat_emerging +0.2% +0.1% — 2026-10-07 sec_top_gappers +0.3% +0.1% — 2026-10-07 sec_top_moat_emerging +0.3% +0.1% — 2026-10-06 sec_top_gappers +0.2% +0.0% — 2026-10-06 sec_top_moat_emerging +0.2% +0.0% —
Lifetime: 0/8 wins · hit-rate 0.0% on +2% intraday
Sympathy Basket MG via industrials · score 15 MMM via industrials · score 14 PVL via materials · score 23 FRTT via materials · score 5 NVDA via semis · score 6 FLEX via semis · score 3
Earnings Catalyst No recent earnings event.
Generate full earnings report
Auto-generated from public filings + tier-1 wires. Catalyst Edge publishes its picks
and its losses — see the
trust report and
methodology .
Not financial advice. Confirm independently before trading.